Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1990 Jun 1;171(6):1957–1963. doi: 10.1084/jem.171.6.1957

Enhanced antigen immunogenicity induced by bispecific antibodies

PMCID: PMC2187948  PMID: 2351931

Abstract

The binding of protein antigens to APC with heterocrosslinked bispecific antibodies (HBAs) enhances their processing and presentation to Th cells in vitro. Here we have asked whether HBAs could also increase immune responses in vivo. We immunized mice with hen egg lysozyme (HEL) in the presence or absence of HBA, and followed antibody production after the primary challenge and after a secondary boost. We found that HBAs that bind antigen to MHC class I or II molecules, to Fc gamma R, but not to surface IgD, enhance the immunogenicity of HEL. HBAs that bound HEL to MHC class II molecules, for examples, decreased the amount of antigen required to elicit a primary anti-HEL antibody response in mice by 300-fold, and the amount required to prime for a secondary response by 10(3)- to 10(4)-fold. In fact, HBAs were as effective as IFA in generating antibody responses. Since adjuvants cannot be used in humans, HBAs could prove useful for immunizing people, especially in cases where, due to scarcity or toxicity, minute doses of antigen must be used.

Full Text

The Full Text of this article is available as a PDF (446.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen P. M., Babbitt B. P., Unanue E. R. T-cell recognition of lysozyme: the biochemical basis of presentation. Immunol Rev. 1987 Aug;98:171–187. doi: 10.1111/j.1600-065x.1987.tb00524.x. [DOI] [PubMed] [Google Scholar]
  2. Ashwell J. D. Are B lymphocytes the principal antigen-presenting cells in vivo? J Immunol. 1988 Jun 1;140(11):3697–3700. [PubMed] [Google Scholar]
  3. Carayanniotis G., Vizi E., Parker J. M., Hodges R. S., Barber B. H. Delivery of synthetic peptides by anti-class II MHC monoclonal antibodies induces specific adjuvant-free IgG responses in vivo. Mol Immunol. 1988 Sep;25(9):907–911. doi: 10.1016/0161-5890(88)90128-9. [DOI] [PubMed] [Google Scholar]
  4. Dietzschold B., Wang H. H., Rupprecht C. E., Celis E., Tollis M., Ertl H., Heber-Katz E., Koprowski H. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9165–9169. doi: 10.1073/pnas.84.24.9165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Edelman R. Vaccine adjuvants. Rev Infect Dis. 1980 May-Jun;2(3):370–383. doi: 10.1093/clinids/2.3.370. [DOI] [PubMed] [Google Scholar]
  6. Gammon G., Shastri N., Cogswell J., Wilbur S., Sadegh-Nasseri S., Krzych U., Miller A., Sercarz E. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev. 1987 Aug;98:53–73. doi: 10.1111/j.1600-065x.1987.tb00519.x. [DOI] [PubMed] [Google Scholar]
  7. Glennie M. J., McBride H. M., Worth A. T., Stevenson G. T. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. J Immunol. 1987 Oct 1;139(7):2367–2375. [PubMed] [Google Scholar]
  8. Goroff D. K., Stall A., Mond J. J., Finkelman F. D. In vitro and in vivo B lymphocyte-activating properties of monoclonal anti-delta antibodies. I. Determinants of B lymphocyte-activating properties. J Immunol. 1986 Apr 1;136(7):2382–2392. [PubMed] [Google Scholar]
  9. Hill S. W., Sercarz E. E. Fine specificity of the H-2 linked immune response gene for the gallinaceous lysozymes. Eur J Immunol. 1975 May;5(5):317–324. doi: 10.1002/eji.1830050506. [DOI] [PubMed] [Google Scholar]
  10. Janeway C. A., Jr, Ron J., Katz M. E. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol. 1987 Feb 15;138(4):1051–1055. [PubMed] [Google Scholar]
  11. Kappler J. W., Skidmore B., White J., Marrack P. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J Exp Med. 1981 May 1;153(5):1198–1214. doi: 10.1084/jem.153.5.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kawamura H., Berzofsky J. A. Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J Immunol. 1986 Jan;136(1):58–65. [PubMed] [Google Scholar]
  13. Kurt-Jones E. A., Liano D., HayGlass K. A., Benacerraf B., Sy M. S., Abbas A. K. The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. J Immunol. 1988 Jun 1;140(11):3773–3778. [PubMed] [Google Scholar]
  14. Lanzavecchia A., Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol. 1987 Jan;17(1):105–111. doi: 10.1002/eji.1830170118. [DOI] [PubMed] [Google Scholar]
  15. Oi V. T., Jones P. P., Goding J. W., Herzenberg L. A., Herzenberg L. A. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr Top Microbiol Immunol. 1978;81:115–120. doi: 10.1007/978-3-642-67448-8_18. [DOI] [PubMed] [Google Scholar]
  16. Ozaki S., Berzofsky J. A. Antibody conjugates mimic specific B cell presentation of antigen: relationship between T and B cell specificity. J Immunol. 1987 Jun 15;138(12):4133–4142. [PubMed] [Google Scholar]
  17. Perez P., Hoffman R. W., Titus J. A., Segal D. M. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies. J Exp Med. 1986 Jan 1;163(1):166–178. doi: 10.1084/jem.163.1.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ron Y., Sprent J. T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. J Immunol. 1987 May 1;138(9):2848–2856. [PubMed] [Google Scholar]
  19. Smith-Gill S. J., Wilson A. C., Potter M., Prager E. M., Feldmann R. J., Mainhart C. R. Mapping the antigenic epitope for a monoclonal antibody against lysozyme. J Immunol. 1982 Jan;128(1):314–322. [PubMed] [Google Scholar]
  20. Snider D. P., Segal D. M. Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MHC, Fc gamma RII, and B220 molecules on murine splenic B cells. J Immunol. 1989 Jul 1;143(1):59–65. [PubMed] [Google Scholar]
  21. Snider D. P., Segal D. M. Targeted antigen presentation using crosslinked antibody heteroaggregates. J Immunol. 1987 Sep 1;139(5):1609–1616. [PubMed] [Google Scholar]
  22. Staerz U. D., Bevan M. J. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1453–1457. doi: 10.1073/pnas.83.5.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Titus J. A., Garrido M. A., Hecht T. T., Winkler D. F., Wunderlich J. R., Segal D. M. Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. J Immunol. 1987 Jun 1;138(11):4018–4022. [PubMed] [Google Scholar]
  24. Unkeless J. C. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med. 1979 Sep 19;150(3):580–596. doi: 10.1084/jem.150.3.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Warren H. S., Vogel F. R., Chedid L. A. Current status of immunological adjuvants. Annu Rev Immunol. 1986;4:369–388. doi: 10.1146/annurev.iy.04.040186.002101. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES